Literature DB >> 31099169

Secukinumab in an HIV-positive patient with psoriasis.

Vito Di Lernia1, Dahiana M Casanova1, Elisa Garlassi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31099169     DOI： 10.1111/ddg.13851

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN： 1610-0379            Impact factor:   5.584


× No keyword cloud information.
  3 in total

1.  TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors.

Authors:  Julie J Hong; Edward K Hadeler; Megan L Mosca; Nicholas D Brownstone; Tina Bhutani; Wilson J Liao
Journal:  J Psoriasis Psoriatic Arthritis       Date:  2022-01-12

Review 2.  Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.

Authors:  Alfonso Motolese; Manuela Ceccarelli; Laura Macca; Federica Li Pomi; Ylenia Ingrasciotta; Giuseppe Nunnari; Claudio Guarneri
Journal:  Biomedicines       Date:  2022-01-21

3.  Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast.

Authors:  Paolo Romita; Caterina Foti; Gianluca Calianno; Andrea Chiricozzi
Journal:  Dermatol Ther       Date:  2022-06-07       Impact factor: 3.858
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.